Pharma & Healthcare in Argentina: Turning a Corner?
Has Argentina, for years one of the economic basket cases of Latin America, finally turned a corner? And is its pharma industry set for a bounce back? Firebrand TV…
The Laboratorio de Hemoderivados of the National University of Córdoba, Argentinian Republic, celebrated its 50th anniversary on May 21st of 2014. Hemoderivados is the only plasma product manufacturer in Argentina 
and it is a role model in terms of nation-wide drug production. Its presence greatly improves access to key medical products for the Argentinian community, regulating market prices and replacing imports.
Laboratorio de Hemoderivados develops, manufactures and markets products that save and improve the lives of people with hemophilia, immune disorders, infectious diseases, kidney and liver disease, trauma, and other chronic and acute medical conditions. These products are used in many countries of the region such as Uruguay, Chile, Ecuador, Bolivia, Paraguay and the Dominican Republic. As a model State-owned non-profit corporation with successful economic and financial self-management, it has significantly diversified its production over the last 50 years, adding to the plasma-derived product line two other production lines: injectable drugs and a human tissue bank.
Laboratorio de Hemoderivados
Universidad Nacional de Córdoba
Av. Valparaíso s/n – Ciudad Universitaria
CP: X5000HRA – Córdoba Capital
T: 54 351 433 4122 / 23
F: 54 351 433 4124
E: laboratorio@hemo.unc.edu.ar
Has Argentina, for years one of the economic basket cases of Latin America, finally turned a corner? And is its pharma industry set for a bounce back? Firebrand TV…
Gustavo Pelizzari leads Elea, Argentina’s largest pharmaceutical company by sales volume, employing 1,350 people. Under his leadership, Elea has achieved the unique distinction of simultaneously leading both the retail pharmaceutical…
Gala Díaz Langou, a senior analyst and executive director at Argentina’s premier think tank CIPPEC, assesses the country’s recent transformative journey under President Milei. Drawing on 25 years of institutional…
Keila Barral, founder of Cromodata, brings together a personal journey of resilience and a career in technology to address one of Latin America’s biggest healthcare challenges: fragmented patient data. After…
Argentina’s pharmaceutical industry combines a robust domestic manufacturing base with growing international reach and regulatory credibility. In this interview, Mauricio Claverí, Chief Economist at CILFA, explores how local companies are…
Juan Jose Marconi, Executive Director of Cooperala, offers a unique perspective shaped by decades of leadership across Argentina’s pharmaceutical and healthcare sectors. With a strong academic background in applied mathematics,…
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
A roundup of some of the biggest stories coming out of Latin American pharma and healthcare, including Mexico’s move to speed up the drug review process; Sanfer’s acquisition of Columbia’s…
A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4…
An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s…
A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s…
See our Cookie Privacy Policy Here
